Navigation Links
Covance Launches Managed Markets Services
Date:8/6/2013

PRINCETON, N.J., Aug. 6, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, announced the creation of a new service offering focused on providing its biopharmaceutical and medical device clients support to effectively manage contracts in managed markets.  Steve Medina, Vice President, Managed Market Services, is leading this new effort.

Covance's managed markets services will help clients maximize value by improving controls and management of contract terms and associated payments.  The new service will also help biopharmaceutical and medical device clients obtain higher market share by gaining better visibility into contract performance with managed care organizations, group purchasing organizations, federal and state programs, and wholesalers.

The service targets a substantial need in the marketplace as chargebacks and rebates used in contracts account for as much as 20 percent of US gross sales for biopharmaceutical and medical device companies (approximately $50 billion a year).  Without the right controls and contracting processes in place, biopharmaceutical and medical device companies risk both revenue loss and potential penalties associated with a failure to comply with government regulations.  It is estimated that biopharmaceutical and medical device companies currently lose up to 4.4 percent of US revenue per year, or $11 billion a year, due to insufficient processes and contract management systems at a time when the economic environment for the sale of drugs and devices has never been more challenging.

"Covance is pleased to have invested in the expertise and technology to help biopharmaceutical and medical device clients prevent significant annual revenue losses from insufficient oversight of the contracts that are used to negotiate price and formulary placement with insurance companies, wholesalers and the government," said Marc Ginsky, Vice President and General Manager, Covance Market Access Services.  "These contracts have become increasingly complex over the past several years and the acquisition and maintenance of the talent and technical infrastructure required to set up, maintain, and manage contracts without revenue leakage is a significant struggle for our clients."

"Covance's managed markets services can transform a labor-intensive, time-consuming, and costly process into a far simpler and more efficient service platform for our clients," said Steve Medina, Vice President, Managed Markets Services.  "We believe that no other company currently offers a full-service, end-to-end solution across all types of contracts and services, with a full technical environment provided as part of the underlying service."

Covance's managed markets services will be led by Steve Medina, who joined Covance in July 2012.  Medina came to Covance from HighPoint Solutions, where he was Vice President, Managed Service.  Prior to this, Medina was the Practice Leader of the BTS Delivery Services Organization within IMS Health, the delivery services organization responsible for providing specialized solutions and on-going services to life sciences companies.  His career includes 23 years of consulting, focused on health care product manufacturing.  He specializes in ongoing service solutions, account management, and systems implementation.  Medina has extensive experience with contract management, as well as sales and marketing.

More information about Covance's managed markets services can be found at www.covance.com/managed-market.

About Covance Inc.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 12,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Forward-Looking Statements
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
2. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2013 Financial Results Conference Call
3. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
4. Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
5. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
6. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
7. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
8. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
9. Covance To Present At The Citi 2013 Global Healthcare Conference
10. Covance To Present At The Leerink Swann Global Healthcare Conference
11. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... NJ (PRWEB) , ... April 28, 2017 , ... Horizon ... has affirmed the company’s credit rating of “A” and its outlook as “stable.” At ... if capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... New york (PRWEB) , ... April 28, 2017 ... ... pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice ... training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique ...
(Date:4/28/2017)... ... 2017 , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit ... at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical ... to donate. , “Women’s Hospital at Renaissance has been a collection partner for ...
Breaking Medicine News(10 mins):